RxDoctor Payments DataLook up a doctor →

Kenneth Carnes, MD

Neurology · Raleigh, NCNPI 1003845363

Payments from drug & device makers

$1,093,852in general payments, 2019–2025

Across 1,528 payments — averaging $715.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$287K
  • Novartis$232K
  • F. Hoffmann-la Roche AG$193K
  • Biogen$179K
  • Adamas Pharmaceuticals, Inc.$58K
  • Roche Products Limited$45K
  • plus $99K from 54 others

What the payments were for

  • Speaking & faculty fees$970%
  • Food & beverage$24,28899%
  • Education$840%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.61$287,085
Novartis78$231,663
F. Hoffmann-la Roche AG63$192,850
Biogen44$178,859
Adamas Pharmaceuticals, Inc.34$58,494
Roche Products Limited27$44,868
Amgen61$38,502
AbbVie(2 entities)220$34,817
Hoffmann-la Roche Limited4$8,603
UCB, Inc.103$2,153
AstraZeneca(2 entities)65$1,401
Lundbeck LLC43$1,069
TG Therapeutics, Inc.27$852
Teva Pharmaceuticals USA, Inc.60$793
Pfizer41$779
Lilly USA, LLC45$623
Impel Pharmaceuticals Inc.33$558
Neurocrine Biosciences, Inc.31$541
Eisai Inc.30$522
Argenx US, Inc.27$465
Boston Scientific6$448
Axsome Therapeutics, Inc.21$413
Sanofi18$403
Neurelis, Inc.23$402
Johnson & Johnson(2 entities)21$374
Grifols USA, LLC18$364
Amneal Pharmaceuticals LLC21$345
EMD Serono, Inc.16$339
Bristol Myers Squibb17$318
Genentech USA, Inc.16$265
Merz Pharmaceuticals, LLC12$232
SK Life Science, Inc.9$225
Upsher-smith Laboratories LLC13$203
Banner Life Sciences, LLC8$202
CSL Behring10$192
Biohaven Pharmaceutical Holding Company Ltd.12$179
Acorda Therapeutics, Inc12$176
Acadia Pharmaceuticals Inc11$146
MDD US Operations, LLC7$141
Otsuka America Pharmaceutical, Inc.8$141
Avion Pharmaceuticals8$140
Sunovion Pharmaceuticals Inc.9$137
Sumitomo Pharma America, Inc.4$131
Catalyst Pharmaceuticals, Inc.4$131
Aucta Pharmaceuticals, Inc.9$130
Avadel CNS Pharmaceuticals, LLC6$126
Jazz Pharmaceuticals Inc.5$126
Biohaven Pharmaceuticals, Inc.6$102
Corium, LLC5$90
Takeda Pharmaceuticals U.S.A., Inc.4$88
Harmony Biosciences LLC3$86
Supernus Pharmaceuticals, Inc.6$84
Kyowa Kirin, Inc.4$84
Assertio Therapeutics, Inc.6$77
Mallinckrodt Hospital Products Inc.4$74
Alnylam Pharmaceuticals Inc.4$73
Aquestive Therapeutics, Inc.4$69
Averitas Pharma Inc.2$66
Sanofi-aventis U.S. LLC1$65
GE HealthCare5$62

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,093,852 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,083,781
Medicare patients
563
Services billed
33,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$97,353
Plegridy PenPeginterferon Beta-1a12$97,032
AustedoDeutetrabenazine13$63,887
Aimovig AutoinjectorErenumab-Aooe66$61,944
Wellbutrin XlBupropion Hcl24$54,706
QuliptaAtogepant37$48,731
Nurtec OdtRimegepant Sulfate15$32,305
Lamictal XrLamotrigine13$28,621
RytaryCarbidopa/Levodopa13$24,607
Keppra XrLevetiracetam18$24,326
TrileptalOxcarbazepine17$21,865
OxycontinOxycodone Hcl23$14,404
Ajovy AutoinjectorFremanezumab-Vfrm15$13,421
Sumatriptan Succinate82$7,991
Gabapentin455$7,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$541$97,35312 claims
Teva Pharmaceuticals USA, Inc.Austedo$793$63,88713 claims
AbbVieQulipta$34,817$48,73137 claims
PfizerNurtec Odt$779$32,30515 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$345$27,59836 claims
Johnson & JohnsonXarelto$374$7,48611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.

Other neurology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →